MAPT and Alzheimer disease: Taken together, our findings provide the first evidence that inhibition of CRMP2 phosphorylation at Ser522 reduces Aβ-induced tau phosphorylation, suggesting a novel mechanism through which CRMP2 modulates tau pathology in AD.